Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma.
Publication
, Journal Article
Walther, PJ
Published in: World J Urol
June 2000
The medical management of hormone-refractory prostate cancer remains difficult and largely palliative. The development of effective antineoplastic agents has been frustrated by difficulty in the establishment of satisfactory objective response criteria for clinical trials. Nevertheless, recent trials indicate that mitoxantrone and spindle toxins such as docetaxel do show activity. Estramustine-based regimens have also been promising, and such combination regimens are now being explored rigorously. Benefiting from new molecular-biologic insights into the pathobiology of prostate cancer, novel strategies targeting new molecular pathways of cell regulation and cell-cell interaction (such as angiogenesis) are also being actively pursued.
Duke Scholars
Published In
World J Urol
DOI
ISSN
0724-4983
Publication Date
June 2000
Volume
18
Issue
3
Start / End Page
216 / 221
Location
Germany
Related Subject Headings
- Urology & Nephrology
- Prostatic Neoplasms
- Male
- Humans
- Antineoplastic Agents
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Walther, P. J. (2000). Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma. World J Urol, 18(3), 216–221. https://doi.org/10.1007/s003450000126
Walther, P. J. “Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma.” World J Urol 18, no. 3 (June 2000): 216–21. https://doi.org/10.1007/s003450000126.
Walther PJ. Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma. World J Urol. 2000 Jun;18(3):216–21.
Walther, P. J. “Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma.” World J Urol, vol. 18, no. 3, June 2000, pp. 216–21. Pubmed, doi:10.1007/s003450000126.
Walther PJ. Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma. World J Urol. 2000 Jun;18(3):216–221.
Published In
World J Urol
DOI
ISSN
0724-4983
Publication Date
June 2000
Volume
18
Issue
3
Start / End Page
216 / 221
Location
Germany
Related Subject Headings
- Urology & Nephrology
- Prostatic Neoplasms
- Male
- Humans
- Antineoplastic Agents
- 3202 Clinical sciences
- 1103 Clinical Sciences